495 related articles for article (PubMed ID: 26194538)
1. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
[TBL] [Abstract][Full Text] [Related]
2. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.
Laidlaw TM; Kidder MS; Bhattacharyya N; Xing W; Shen S; Milne GL; Castells MC; Chhay H; Boyce JA
Blood; 2012 Apr; 119(16):3790-8. PubMed ID: 22262771
[TBL] [Abstract][Full Text] [Related]
3. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
4. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
Ledford DK; Wenzel SE; Lockey RF
J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
[TBL] [Abstract][Full Text] [Related]
5. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
[TBL] [Abstract][Full Text] [Related]
6. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease.
Comhair SAA; Bochenek G; Baicker-McKee S; Wang Z; Stachura T; Sanak M; Hammel JP; Hazen SL; Erzurum SC; Nizankowska-Mogilnicka E
Respir Res; 2018 Oct; 19(1):210. PubMed ID: 30376852
[TBL] [Abstract][Full Text] [Related]
7. Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
Mastalerz L; Januszek R; Kaszuba M; Wójcik K; Celejewska-Wójcik N; Gielicz A; Plutecka H; Oleś K; Stręk P; Sanak M
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt B):163-9. PubMed ID: 26209241
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease.
Laidlaw TM; Cutler AJ; Kidder MS; Liu T; Cardet JC; Chhay H; Feng C; Boyce JA
J Allergy Clin Immunol; 2014 Jun; 133(6):1692-701.e3. PubMed ID: 24486071
[TBL] [Abstract][Full Text] [Related]
9. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
10. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.
Bochenek G; Kuschill-Dziurda J; Szafraniec K; Plutecka H; Szczeklik A; Nizankowska-Mogilnicka E
J Allergy Clin Immunol; 2014 Jan; 133(1):98-103.e1-6. PubMed ID: 23993879
[TBL] [Abstract][Full Text] [Related]
11. Platelets in patients with aspirin-exacerbated respiratory disease.
Laidlaw TM; Boyce JA
J Allergy Clin Immunol; 2015 Jun; 135(6):1407-14; quiz 1415. PubMed ID: 26051947
[TBL] [Abstract][Full Text] [Related]
12. Effect of TGF-β1 on eosinophils to induce cysteinyl leukotriene E4 production in aspirin-exacerbated respiratory disease.
Choi Y; Sim S; Lee DH; Lee HR; Ban GY; Shin YS; Kim YK; Park HS
PLoS One; 2021; 16(8):e0256237. PubMed ID: 34437574
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions.
Riondino S; Martini F; La Farina F; Spila A; Guadagni F; Ferroni P
Clin Biochem; 2010 May; 43(7-8):666-70. PubMed ID: 20060822
[TBL] [Abstract][Full Text] [Related]
14. Plasma apolipoprotein H levels are different between aspirin induced respiratory diseases and aspirin tolerant asthma.
Kim HJ; Park JS; Heo JS; Moon KY; Park CS
Pulm Pharmacol Ther; 2014 Apr; 27(2):184-9. PubMed ID: 24120690
[TBL] [Abstract][Full Text] [Related]
15. A trial of type 12 purinergic (P2Y
Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
[TBL] [Abstract][Full Text] [Related]
16. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Steinke JW; Liu L; Huyett P; Negri J; Payne SC; Borish L
J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
[TBL] [Abstract][Full Text] [Related]
17. Elevated platelet activation in patients with chronic urticaria: a comparison between aspirin-intolerant and aspirin-tolerant groups.
Palikhe S; Palikhe NS; Kim SH; Yoo HS; Shin YS; Park HS
Ann Allergy Asthma Immunol; 2014 Sep; 113(3):276-81. PubMed ID: 25037610
[TBL] [Abstract][Full Text] [Related]
18. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
19. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
Wang XS; Wu AY; Leung PS; Lau HY
Allergy; 2007 Jun; 62(6):620-7. PubMed ID: 17508965
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of platelet activation markers in aspirin-sensitive asthmatics and normal subjects.
Taylor ML; Misso NL; Stewart GA; Thompson PJ
Clin Exp Allergy; 1996 Feb; 26(2):202-15. PubMed ID: 8835129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
